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roquinolones has been recommended for prevention of
bacterial infections in HSCT recipients. Our center has used
oral ciproﬂoxacin and penicillin V, started from beginning of
preparative regimen until engraftment, for bacterial infec-
tion prophylaxis. The objective of this study was to analyze
the prevalence and risk factor of breakthrough bacteremia
during neutropenic episodes in childhood HSCT patients.
There were 215 patients (M:F¼1.26:1) with a median age of
8.32 years (range, 0.51-21.64 years) during 2006-2014. The
common underlying diseases were thalassemia and acute
leukemia. The median day of receiving antibiotic prophylaxis
was 11 days (range, 1-38 days). The most common reason for
discontinuation of antibiotic prophylaxis was febrile
neutropenia (64.5%). Microbiologically documented bacterial
infections were found in 66 patients (30.7%) which 33
patients (15.3%) had bacteremia. Escherichia coli (n¼13) was
the most commonly isolated gram negative bacteria while
Staphylococcus spp. (n¼3) and Streptococcus spp. (n¼3) were
the two most common gram positive bacteria. Risk factor
for bacteremia was receiving ATG-containing regimen (OR
2.67; 95%CI, 1.24-5.77). Other characteristics including age,
diagnosis, preparative regimen, source of stem cells, or
type of donor was not associated with bacteremia. Patients
with bacteremia had a higher rate of mortality compared to
those without bacteremia (36.4% vs 13.3%, p¼0.001). No
serious complication associated with ciproﬂoxacin or
penicillin V was found in this study. In conclusion, this study
demonstrated the feasibility and efﬁcacy of ciproﬂoxacin and
penicillin V prophylaxis in children underwent HSCT.
ATG-containing preparative regimen was the signiﬁcant risk
for bacteremia during neutropenic episodes.339
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Background: Glucocorticoids used to treat acute graft-
versus-host-disease (GVHD) are thought to blunt clinical
symptoms of infection. We set out to address the value of
weekly surveillance blood cultures drawn from patients
receiving high-dose glucocorticoids in the outpatient
department (OPD), and to characterize isolated pathogens,
antibiotic use and outcomes in patients undergoing such
surveillance.
Methods: We conducted a retrospective review of blood
cultures collected from a cohort of hematopoietic cell
transplantation (HCT) patients enrolled in a clinical trial of
GVHD ( grade II) therapy who were treated with high-dose
glucocorticoids (deﬁned as a prednisone dose  0.5 mg/kg/
day). Surveillance blood cultures were deﬁned as those
collected weekly in the OPD while patients were receiving
high-dose glucocorticoids. Cultures obtained as part of a
symptom work-up (e.g. fevers, chills or rigors) or as
follow-up for documented bacteremia were considered
non-surveillance cultures. Clinical data were collected using
center databases supplemented by medical record review.Results: A total of 138 adult HCT recipients were eligible for
inclusion in the study. Patients were excluded from analyses
if they never had surveillance blood cultures (n¼7) or were
inpatient during the study period (n¼4). Of the remaining
127 subjects, 1082 outpatient cultures were obtained, for a
median of 8 cultures (interquartile range [IQR]; 5-10) per
patient; the majority of which were surveillance cultures
(1020 [94%]). Bacteria were isolated from 48 of 1082
cultures (4.4%), or 1 positive culture per 24.5 blood cultures
drawn. Signiﬁcantly fewer surveillance compared to
non-surveillance cultures isolated organisms (41/1020 [4.0%]
vs. 7/82 [8.5%], p¼0.007). The most frequently detected
pathogen was coagulase-negative Staphylococcus (28/1082
[2.7%]). Gram negative rod (GNR) pathogens were rare
(10/1082 [0.9%], 3 Serratia, 2 Enterobacter and 1 Pseudo-
monas, E. coli, Bacteroides, Stenotrophomonas and
Klebsiella), and a similar number GNRs were detected
from surveillance and non-surveillance cultures (p¼0.56).
Antibiotics were administered to nearly all patients with
positive surveillance cultures (38/41 [93%]), and one in 4 was
admitted to the hospital for treatment; none needed ICU care
or died from their infection.
Conclusions: Weekly outpatient surveillance blood cultures
obtained from hematopoietic allograft recipients on high-
dose glucocorticoids were infrequently positive, and the
majority of isolates were low-risk pathogens. Although this
screening approach appeared to have limited value and may
lead to excess antibiotic exposure, future prospective studies
are needed to conﬁrm our ﬁndings in this high-risk
population.340
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Abstract: Patients undergoing hematopoietic stem cell
transplantation or myelosuppressive chemotherapy for solid
and hematologic malignancies have the propensity to
develop thrombocytopenia to the point where they will
require prophylactic platelet transfusions once their level
falls below ten thousand. In our institution, the primary
replacement product is single donor platelets. Recently,
there has been the advent of Acrodose platelets which are
obtained from whole blood. These platelets are leuko-
reduced, ABO matched, pooled and bacteria tested making
them “transfusion ready” for the hospital. It lowers handling
costs at the hospital by eliminating the need for pooling and
bacterial testing at the hospital. The Acrodose system can
detect >1 CFU/ml of bacteria at a rate of 99.3% thus reducing
the risks of false positives. Each unit of Acrodose platelets
contains pools of 4-6 units of leuko-reduced platelet
concentrates in plasma.
Methods: Data was collected from October 2012 to October
2013. Therewere a total of 349 platelet transfusions given, 61
were Acrodose and 288 were single donor. There were 17
bone marrow transplant patients of which 16 were autolo-
gous (7 had multiple myeloma, 8 had Non-Hodgkin’s lym-
phoma and 1 had POEMS syndrome) and 1 was allogeneic for
chronic lymphocytic leukemia. In addition, there were 20
acute leukemia patients. The bone marrow transplant
patients received a total of 45 platelet transfusions of which
37 were single donor and 8 were Acrodose. The acute leu-
kemia patients received a total of 150 platelet transfusions of
which 17 were Acrodose and 133 were single donor.
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Acrodose versus single donor platelets was 28.9 versus 19.8,
respectively. The median increase for Acrodose versus single
donor was 28 versus 16. The median time to next transfusion
for Acrodose versus single donor was 4 versus 2 days. In
subgroup analysis, the average increase among bonemarrow
transplant patients receiving Acrodose versus single donor
platelets was 21.7 versus 27.8, respectively. The median
increase for Acrodose versus single donor was 18 versus 20.
The median time to next transfusion for Acrodose versus
single donor was the same at 3 days. Among acute leukemia
patients, the average increase in patients receiving Acrodose
versus single donor platelets was 28 versus 18.6, respectively.
Themedian increase for Acrodose versus single donor was 27
versus 15. The median time to next transfusion for Acrodose
versus single donor was 4 versus 2 days.
Conclusion: In our single institutional experience, Acodose
platelets induced a more robust response and increased the
time to next transfusion compared to single donor platelets
among all patients and especially acute leukemia patients,
however this was not seen with the bone marrow transplant
patients. The reason for this is unclear andmore studies need
to be done.341
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Background: Human rhinovirus (HRV) is well known to
cause upper or lower respiratory tract infection (URTI/LRTI)
and is associated with increased morbidity and mortality in
immunocompromised adults such as those with cancer or
those undergoing hematopoietic stem cell transplantation
(HSCT). Asymptomatic children who are about to undergo
HSCT with a positive respiratory viral panel (RVP) pose a
special challenge and create a dilemma for providers when
deciding whether to move forward with HSCT in patients
with active viral disease.
Methods: We retrospectively reviewed the medical records
of all children who underwent HSCT from Jan 1, 2006 eMay
1, 2014 who had a RVP by PCR performed as part of the
pretransplant workup or within 180 days following HSCT.
Patients with rhinovirus identiﬁed pretransplant were not
treated with IVIG but received routine prophylaxis with IVIG.
Patients who developed rhinoviral infection were treated
with high dose IVIG. We reviewed data of all patients to
evaluate its impact on overall outcome. Demographic,
clinical, microbiologic, management, and outcome data were
collected.
Results: 50 pediatric HSCT patients were identiﬁed. A total of
23 patients were asymptomatic and identiﬁed on pretrans-
plant DFA screening. None of these patients developed
complications related to rhinovirus during the transplant. 21
patients were identiﬁed after HSCT was started due to
workup for fever or respiratory symptoms. None of these
children appeared to have signiﬁcant morbidity and
mortality related to rhinoviral infection. Of note,11/11 (100%)
umbilical cord recipients continued to have positive RVP and
viral shedding for several months following HSCT.Conclusions: Rhinovirus does not appear to have a negative
impact on the course of children undergoing HSCT.
The presence of rhinovirus is not a contraindication to
proceeding to transplant in children. Umbilical cord blood
transplant patients appeared to have delayed clearance of
the virus but this did not impact their clinical outcome.342
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Purpose: The objective of this studywas to compare the time
to engraftment of autologous hematopoietic stem cell
transplant (HSCT) patients who received ﬁlgrastim on day +5
versus day +10. In addition, number of febrile days, antibiotic
use, documented infection, and length of hospitalization
were compared. We hypothesized that duration of neu-
tropenia and incidence of neutropenic fever would be similar
in patients who received ﬁlgrastim on day +5 versus day +10.
Methods: Prior to initiation, the study received approval
from the Institutional Review Board. A HSCT database was
used to identify patients who have received autologous HSCT
from January 1, 2007 to June 30, 2013. Patients were included
if they received ﬁlgrastim on day +5 + 1 or day +10 + 1 post
HSCT. Patients werematched based on age + 5 years and type
of malignancy. The health-system’s electronicmedical record
system, HSCT database, and medication charts were used to
collect the following data: age, gender, weight, height, type
of malignancy requiring transplant, date of autologous
HSCT, chemotherapy conditioning regimen, ﬁlgrastim and
antibiotic administration, documented infections, length of
stay, and survival.
Results: There were 79-matched pairs that met inclusion
criteria. The day +5 group had an average time to engraft-
ment of 8.27 days compared to 8.96 days in the day +10
group (p¼0.006). All secondary endpoints were similar
between both groups, including rates of infection and total
febrile days. There was no difference seen with average
length of stay between the two groups (p¼0.745).
Conclusion: The average time to engraftment was
statistically signiﬁcant, in favor of patients who received
ﬁlgrastim earlier in their transplant course on day +5.
However the primary and secondary endpoints results are
not clinically signiﬁcant. Future directions include a cost
analysis to assess economic outcomes.343
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